Histone Acetyltransferase

HATs; HAT

Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs are crucial for chromatin restructuring and transcriptional regulation in eukaryotic cells. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins.

HATs can be grouped into at least five different subfamilies (HAT1, Gcn5/PCAF, MYST, p300/CBP, and Rtt109). HATs mediate many different biological processes including cell-cycle progression, dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function is correlated with several human diseases including solid tumors, leukemias, inflammatory lung disease, viral infection, diabetes, fungal infection, and drug addiction.

Histone Acetyltransferase Inhibitors & Activators

A-485

Cat. No.: HY-107455

A-485 is a potent and selective catalytic inhibitor of **p300/CBP** with IC_{50}s of 9.8nM and 2.6nM for **p300** and **CBP** histone acetyltransferase (HAT), respectively.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Acetaminophen

(Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide) Cat. No.: HY-66005

Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent **hepatic N-acetyltransferase 2 (NAT2)** inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 500 mg, 5 g, 10 g

Acetaminophen-13C6 (Paracetamol-13C6; 4-Acetamidophenol-13C6; 4'-Hydroxyacetanilide-13C6)

Cat. No.: HY-66005S3

Acetaminophen-13C6 (Paracetamol-13C6) is the 13C-labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetaminophen-d3 (Paracetamol-d3; 4-Acetamidophenol-d3; 4'-Hydroxyacetanilide-d3)

Cat. No.: HY-66005S1

Acetaminophen-d3 (Paracetamol-d3) is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Acetaminophen-d4

Cat. No.: HY-66005S

Acetaminophen-d4 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent **hepatic N-acetyltransferase 2 (NAT2)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Anacardic Acid

(Hydroginkgolic acid; Ginkgolic Acid C15:0) Cat. No.: HY-N2020

Anacardic Acid, extracted from cashew nut shell liquid, is a **histone acetyltransferase** inhibitor, inhibits HAT activity of p300 and PCAF, with IC_{50}s of 8.5 μM and 5 μM, respectively.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Butyrolactone 3

(MB-3) Cat. No.: HY-129039

Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the **histone acetyltransferase Gcn5** (IC_{50}=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

C646

Cat. No.: HY-13823

C646 is a selective and competitive **histone acetyltransferase p300** inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CBP/p300-IN-12

Cat. No.: HY-132197

CBP/p300-IN-12 is a potent and selective covalent **histone acetyltransferases p300** (IC_{50} of 166 nM) and **CBP** inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC_{50} of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CBP/p300-IN-14

Cat. No.: HY-139861

CBP/p300-IN-14 is a potent inhibitor of **CBP/EP300** (lysine acetyltransferase) with an IC_{50} of 3.3 nM (extracted from patent WO2021213521A1, compound 27).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

CBP/p300-IN-3

Cat. No.: HY-128876

CBP/p300-IN-3, a p300/CBP **histone acetyltransferase** inhibitor, Compound 6, is sourced from patent WO 2019049061 A1.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CBP/p300-IN-5

Cat. No.: HY-100132

P300/CBP-IN-5 is a potent **p300/CBP histone acetyltransferase** inhibitor extracted from patent WO2016044770A1, Example 715, has an IC_{50} of 18.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

CF53

Cat. No.: HY-112610

CF53 is a highly potent, selective and orally active inhibitor of **BET** protein, with a K_i of <1 nM, K_d of 2.2 nM and an IC_{50} of 2 nM for BRD4 BD1.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Coumarin-SAHA

Cat. No.: HY-126829

Coumarin-SAHA is a **fluorescent probe** for determining the binding affinities (k_d) and the dissociation off-rates (k_{off}) of the HDAC8-inhibitor complexes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPI-1612

Cat. No.: HY-136285

CPI-1612 is a highly potent, orally active **EP300/CBP histone acetyltransferase (HAT)** inhibitor with an IC_{50} of 8.1 nM for **EP300 HAT**. CPI-1612 has an anticancer activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPI-637

Cat. No.: HY-100482

CPI-637 is a selective and potent **CBP/EP300** bromodomain inhibitor with IC_{50} values of 0.03 μM, 0.051 μM and 11.0 μM for **CBP**, **EP300** and **BRD4 BD-1**, respectively, and an EC_{50} of 0.3 μM for **CBP**.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CPTH2

Cat. No.: HY-W013274

CPTH2 is a potent **histone acetyltransferase (HAT)** inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by **Gcn5**. CPTH2 induces **apoptosis** and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of **acetyltransferase p300 (KAT3B)**.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CPTH2 hydrochloride

Cat. No.: HY-W013274A

CPTH2 hydrochloride is a potent **histone acetyltransferase (HAT)** inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by **Gcn5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CTB

Cat. No.: HY-134964

CTB is a potent **p300 histone acetyltransferase** activator. CTB can effectively induce **apoptosis** in MCF-7 cells.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CTPB

Cat. No.: HY-124960

CTPB is a good activator of **p300 histone acetyl transferase** (**HAT**) enzyme.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Curcumin

(Diferuloylmethane; Natural Yellow 3; Turmeric yellow) **Cat. No.:** HY-N0005

Curcumin (Diferuloylmethane), a natural phenolic compound, is a **p300/CREB-binding protein-specific** inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.



Purity: ≥96.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Curcumin-d6 (Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6)

Cat. No.: HY-N0005S

Curcumin D6 (Diferuloylmethane D6) is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DCH36_06

Cat. No.: HY-139108

DCH36_06 is a potent and selective **p300/CBP** inhibitor with **IC_{50}**s of 0.6 μM and 3.2 μM for **p300** and **CBP**, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EML 425

Cat. No.: HY-110263

EML425 is a potent and selective CREB binding protein (**CBP**)/**p300** inhibitor with **IC_{50}**s of 2.9 and 1.1 μM, respectively.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Garcinol

Cat. No.: HY-107569

Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards **acetyl cholinesterase (AChE)** and **butyrylcholinesterase (BChE)** with **IC_{50}**s of 0.66 μM and 7.39 μM, respectively.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

GNE-049

Cat. No.: HY-108435

GNE-049 is a highly potent and selective **CBP** inhibitor with an **IC_{50}** of 1.1 nM in TR-FRET assay. GNE-049 also inhibits **BRET** and **BRD4(1)** with **IC_{50}**s of 12 nM and 4200 nM, respectively.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-207

Cat. No.: HY-120028

GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of **CBP**, with an **IC_{50}** of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an **EC_{50}** of 18 nM for MYC expression in MV-4-11 cells.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GNE-272

Cat. No.: HY-100726

GNE-272 is a potent and selective **CBP/EP300** inhibitor with **IC_{50}** values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GNE-781

Cat. No.: HY-108696

GNE-781 is an orally active, highly potent and selective **CBP** inhibitor with an **IC_{50}** of 0.94 nM in TR-FRET assay. GNE-781 also inhibits **BRET** and **BRD4(1)** with **IC_{50}**s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK 4027

Cat. No.: HY-101027

GSK 4027 is a chemical probe for the **PCAF/GCN5 bromodomain** with an **pIC_{50}** of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK4028

Cat. No.: HY-101027A

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the **pIC$_{50}$** of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HAT-IN-1

Cat. No.: HY-103669

HAT-IN-1 is an inhibitor of **HAT**, used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Histone Acetyltransferase Inhibitor II

Cat. No.: HY-100734

Histone Acetyltransferase Inhibitor II (compound 2c) is a potent, selective and cell permeable **p300 histone acetyltransferase** inhibitor, with an **IC$_{50}$** of 5 μM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

I-CBP112

Cat. No.: HY-19541

I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the **CBP/p300** bromodomains, enhances acetylation by p300.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

L002

Cat. No.: HY-100671

L002 is a potent, cell permeable, reversible and specific **acetyltransferase p300 (KAT3B)** inhibitor with an **IC$_{50}$** of 1.98 μM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lys-CoA TFA

Cat. No.: HY-131035

Lys-CoA TFA is a selective **p300** histone acetyltransferase (HAT) inhibitor (**IC$_{50}$**=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC$_{50}$=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MG 149

(Tip60 HAT inhibitor)

Cat. No.: HY-15887

MG149 (Tip60 HAT inhibitor) is a selective and potent **Tip60** inhibitor with **IC$_{50}$** of 74 uM, similar potentcy for **MOF** (**IC$_{50}$**= 47 uM); little potent for PCAF and p300 (IC$_{50}$ >200 uM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MOZ-IN-2

Cat. No.: HY-102059

MOZ-IN-2 is an inhibitor of protein **MOZ**, a member of histone acetyltransferases, with an **IC$_{50}$** of 125 μM.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Naphthol AS-E

Cat. No.: HY-104068

Naphthol AS-E is a potent and cell-permeable inhibitor of **KIX-KID interaction**. Naphthol AS-E directly binds to the KIX domain of CBP (**K$_d$**:8.6 μM), blocks the interaction between the KIX domain and the KID domain of CREB with **IC$_{50}$** of 2.26 μM. Naphthol AS-E can be used for cancer research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

NEO2734

(EP31670)

Cat. No.: HY-136938

NEO2734 (EP31670) is an orally active dual **p300/CBP** and **BET bromodomain** selective inhibitor, with **IC$_{50}$** values of <30 nM for both p300/CBP and BET bromodomains. NEO2734 is active in SPOP mutant and wild-type prostate cancer.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NiCur

Cat. No.: HY-139149

NiCur is a potent and selective **CBP histone acetyltransferase (HAT)** inhibitor with an IC_{50} value of 0.35 μM. NiCur, which blocks **CBP HAT** activity and downregulates p53 activation upon genotoxic stress.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NU9056

Cat. No.: HY-110127

NU9056 is a potent and selective **Tip60 (KAT5) histone acetyltransferase** inhibitor with an of 2 μM. NU9056 shows >16-fold selectivity for **Tip60** over PCAF, p300 and GCN5. NU9056 induces **apoptosis** of prostate cancer cells.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

P300 bromodomain-IN-1

Cat. No.: HY-146445

P300 bromodomain-IN-1 (Compoun 1u) is a potent **p300 (EP300) bromodomain** inhibitor with an IC_{50} of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and **apoptosis** in OPM-2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-9363

(CTx-648)

Cat. No.: HY-132283

PF-9363 (CTx-648) is a first-in-class potent and high selective **KAT6A/KAT6B** inhibitor. PF-9363 can be used for the research of cancer.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-CBP1 hydrochloride

Cat. No.: HY-19999A

PF-CBP1 hydrochloride is a highly selective inhibitor of the **CREB binding protein bromodomain (CBP BRD)**. PF-CBP1 inhibits **CREBBP** and **EP300 bromodomains** with IC_{50} of 125 nM and 363 nM respectively.



Purity: 95.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Procyanidin B3

Cat. No.: HY-N2345

Procyanidin B3 is a natural product, acts as a specific **HAT** inhibitor, binds to the other site of **p300** instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase).



Purity: 99.63%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PU139

Cat. No.: HY-124696

PU139 is a potent pan-histone acetyltransferase **(HAT)** inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC_{50}s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PU141

Cat. No.: HY-120290

PU141 is a selected pyridoisothiazolone **HAT** inhibitor. PU141 is selective toward **CBP** and **p300**. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Remodelin

Cat. No.: HY-16706

Remodelin is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Remodelin hydrobromide

Cat. No.: HY-16706A

Remodelin, a specific inhibitor of N-acetyltransferase **NAT10**, can ameliorate Hutchinson-Gilford Progeria Syndrom (HGPS) cellular phenotypes. Remodelin acts in a progerin- and FTI-independent pathway, by targeting and inhibiting NAT10.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SGC-CBP30

Cat. No.: HY-15826

SGC-CBP30 is a potent and highly selective **CBP/p300 bromodomain** (K_ds of 21 nM and 32 nM for **CBP** and **p300**, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of **BRD4 [BRD4(1)]** bound.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SYY-B085-1

Cat. No.: HY-138945

SYY-B085-1 is a **histone acetyltransferase (HAT)** inhibitor extracted from patent WO2019201291A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TH1834

Cat. No.: HY-123604

TH1834 is a specific **Tip60 (KAT5) histone acetyltransferase (HAT)** inhibitor. TH1834 induces **apoptosis** and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TH1834 dihydrochloride

Cat. No.: HY-123604A

TH1834 dihydrochloride is a specific **Tip60 (KAT5) histone acetyltransferase** inhibitor. TH1834 dihydrochloride induces **apoptosis** and increases DNA damage in breast cancer. TH1834 dihydrochloride does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TPOP146

Cat. No.: HY-100697

TPOP146 is a selective **CBP/P300** benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TTK21

Cat. No.: HY-116673

TTK21 is an activator of the histone acetyltransferases **CBP/p300**. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP).



Purity: 99.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WM-1119

Cat. No.: HY-102058

WM-1119 is a highly potent and selective **KAT6A** inhibitor, with an IC_{50} of 0.25 μM for KAT6A in lymphoma cells, the binding K_D values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 μM, 0.5 μM , respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WM-3835

Cat. No.: HY-134901

WM-3835 is a potent and high-specific **HBO1** (**KAT7** or **MYST2**) inhibitor and binds directly to the acetyl-CoA binding site of HBO1 33. WM-3835 activates **apoptosis** while inhibits osteosarcoma (OS) cell proliferation, migration and invasion.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WM-8014

Cat. No.: HY-102060

WM-8014 is an inhibitor of **MOZ**, a member of **histone acetyltransferases**, with an IC_{50} of 55 nM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YF-2

Cat. No.: HY-16531

YF-2 is a highly selective, blood-brain-barrier permeable **histone acetyltransferase** activator, acetylates H3 in the hippocampus, with **EC_{50}**s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YF-2 hydrochloride

Cat. No.: HY-16531A

YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable **histone acetyltransferase** activator, acetylates H3 in the hippocampus, with **EC_{50}**s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg